Bosh sahifa207940 • KRX
add
Samsung Biologics Co Ltd
Yopilish kursi
1 766 000,00 ₩
Kunlik diapazon
1 741 000,00 ₩ - 1 778 000,00 ₩
Yillik diapazon
982 000,00 ₩ - 1 987 000,00 ₩
Bozor kapitalizatsiyasi
82,31 trln KRW
Oʻrtacha hajm
60,28 ming
Narx/foyda
51,57
Dividend daromadliligi
-
Bozor yangiliklari
Simply Wall St
1 soat oldin
Morningstar Expands Retirement Reach And Data Platform With New Leadership
0,46%
Moliyaviy axborot
Moliyaviy hisobot
Daromad
Sof foyda
| (KRW) | dek, 2025info | Y/Y qiyosi |
|---|---|---|
Daromad | 1,29 trln | 2,35% |
Joriy xarajat | 144,00 mlrd | -56,91% |
Sof foyda | 510,00 mlrd | 58,63% |
Sof foyda marjasi | 39,66 | 54,98% |
Har bir ulushga tushum | 5,72 ming | -17,60% |
EBITDA | — | — |
Amaldagi soliq stavkasi | 21,22% | — |
Balans
Jami aktivlari
Jami passivlari
| (KRW) | dek, 2025info | Y/Y qiyosi |
|---|---|---|
Naqd pul va qisqa investitsiyalar | 1,46 trln | 9,37% |
Jami aktivlari | 11,06 trln | -36,20% |
Jami passivlari | 3,61 trln | -43,87% |
Umumiy kapital | 7,45 trln | — |
Tarqatilgan aksiyalar | 46,29 mln | — |
Narxi/balansdagi bahosi | 10,97 | — |
Aktivlardan daromad | — | — |
Kapitaldan daromad | — | — |
Pul aylanmasi
Naqd pulning sof oʻzgarishi
| (KRW) | dek, 2025info | Y/Y qiyosi |
|---|---|---|
Sof foyda | 510,00 mlrd | 58,63% |
Operatsiyalardan naqd pul | — | — |
Sarmoyadan naqd pul | — | — |
Moliyadan naqd pul | — | — |
Naqd pulning sof oʻzgarishi | — | — |
Boʻsh pul | — | — |
Haqida
Samsung Biologics Co., Ltd. is a global contract development and manufacturing organization headquartered in Songdo, Incheon, South Korea. The biotech division of Samsung Group, its core services range from late discovery to large-scale commercial manufacturing. The company focuses on monoclonal antibodies, bispecific antibodies, antibody-drug conjugates, and mRNA vaccines.
The company has partnered with pharmaceutical companies such as Pfizer, GlaxoSmithKline, Eli Lilly, AstraZeneca and Bristol-Myers Squibb. Wikipedia
CEO
Tashkil etilgan
2011
Xodimlar soni
4 770
